University Of Texas Investment Managment Co adds Agios Pharmaceuticals Inc (AGIO) to its portfolio

Agios Pharmaceuticals Inc (AGIO) : University Of Texas Investment Managment Co added new position in Agios Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 40,000 shares of Agios Pharmaceuticals Inc which is valued at $1,616,800 , the company said in a statement filed on Aug 11, 2016 with the SEC.Agios Pharmaceuticals Inc makes up approximately 4.71% of University Of Texas Investment Managment Co’s portfolio.

Other Hedge Funds, Including , Canada Pension Plan Investment Board reduced its stake in AGIO by selling 100 shares or 0.9% in the most recent quarter. The Hedge Fund company now holds 11,000 shares of AGIO which is valued at $444,620.Teacher Retirement System Of Texas boosted its stake in AGIO in the latest quarter, The investment management firm added 1,136 additional shares and now holds a total of 3,921 shares of Agios Pharmaceuticals Inc which is valued at $159,310. Finemark National Bank Trust added AGIO to its portfolio by purchasing 196 company shares during the most recent quarter which is valued at $7,826. Cambridge Investment Research Advisors added AGIO to its portfolio by purchasing 15,300 company shares during the most recent quarter which is valued at $659,736. Agios Pharmaceuticals Inc makes up approx 0.01% of Cambridge Investment Research Advisors’s portfolio. Candriam Luxembourg S.c.a. sold out all of its stake in AGIO during the most recent quarter. The investment firm sold 40,000 shares of AGIO which is valued $1,822,400.

Agios Pharmaceuticals Inc opened for trading at $40.56 and hit $41.365 on the upside on Tuesday, eventually ending the session at $40.99, with a gain of 1.69% or 0.68 points. The heightened volatility saw the trading volume jump to 5,06,304 shares. Company has a market cap of $1,560 M.

On the company’s financial health, Agios Pharmaceuticals Inc reported $-1.47 EPS for the quarter, missing the analyst consensus estimate by $ -0.17 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.30. The company had revenue of $6.97 million for the quarter, compared to analysts expectations of $41.37 million. The company’s revenue was down -47.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.85 EPS.

Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Agios Pharmaceuticals Inc was Upgraded by JP Morgan to ” Overweight” on Jun 13, 2016. Company shares were Reiterated by SunTrust on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Company shares were Reiterated by Sun Trust Rbsn Humphrey on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .

Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *